Vyzulta Side Effects

Generic Name: latanoprostene bunod ophthalmic

Medically reviewed by Drugs.com. Last updated on Oct 4, 2020.

Consumer
Professional

Note: This document contains side effect information about latanoprostene bunod ophthalmic. Some of the dosage forms listed on this page may not apply to the brand name Vyzulta.

For the Consumer

Applies to latanoprostene bunod ophthalmic: ophthalmic solution

Side effects requiring immediate medical attention

Along with its needed effects, latanoprostene bunod ophthalmic (the active ingredient contained in Vyzulta) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking latanoprostene bunod ophthalmic:

More common

Redness of the white part of the eyes or the inside of the eyelids

Less common

Eye irritation

Rare

Painful irritation of the clear front part of the eye swelling of the eye and the lining of the eyelid

Incidence not known

Blurred vision or other change in vision
decreased vision
eye pain
redness of the eye
sensitivity of the eye to light
tearing

Side effects not requiring immediate medical attention

Some side effects of latanoprostene bunod ophthalmic may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Rare

Feeling of having something in the eye

Incidence not known

Increased brown color in the colored part of the eye longer, thicker, and darker eyelashes

For Healthcare Professionals

Applies to latanoprostene bunod ophthalmic: ophthalmic solution

General

The most frequently reported side effects were conjunctival hyperemia, eye irritation, eye pain, and instillation site pain.^[Ref]

Ocular

Common (1% to 10%): Conjunctival hyperemia, eye irritation, eye pain, instillation site pain

Frequency not reported: Foreign body sensation, punctate keratitis, vision blurred, conjunctival edema, conjunctival irritation^[Ref]

About 0.6% of patients discontinued therapy due to ocular adverse reactions including ocular hyperemia, conjunctival irritation, eye irritation, eye pain, conjunctival edema, vision blurred, punctate keratitis, and foreign body sensation.^[Ref]